Heart Failure Drug Shows Beneficial Metabolic Effects in PARADIGM-HF Trial

Video

Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, detailed study results for sacubitril/valsartan the first angiotensin receptor neprilysin inhibitor to be approved by the FDA for its indication.

Sacubitril/valsartan (Entresto/Novartis) became the first angiotensin receptor neprilysin inhibitor for to be approved for chronic heart failure with reduced ejection fraction (HFrEF) by the US Food and Drug Administration (FDA) in July 2015. In the PARADIGM-HF trial, the drug combination was observed in patients with a history of type 2 diabetes and HFrEF.

Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, revealed the results of PARADIGM-HF to MD Magazine during an interview at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia.

“We didn’t expect to see this,” Solomon said. “The trial was designed as a heart failure trial, but here we have a heart failure drug that also has very beneficial metabolic effects as well.”

This information becomes very important for doctors who treat patients with heart failure who also have diabetes, Solomon said.

>>> More Coverage from ACC 2017

Related Videos
Why Are Adult ADHD Cases Climbing?
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Robert Rosenson, MD | Credit: Cura Foundation
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Optimizing Diabetes Therapies with New Classifications
Anthony Lembo, MD | Credit: Cleveland Clinic
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
© 2024 MJH Life Sciences

All rights reserved.